Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Caspi, O.
Right arrow Articles by Gepstein, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Caspi, O.
Right arrow Articles by Gepstein, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Stem cells for myocardial repair

Oren Caspi and Lior Gepstein*

Sohnis Family Research Laboratory for Cardiac Electrophysiology and Regenerative Medicine and the Rappaport Family Institute for Research in the Medical Sciences, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 2 Efron Street, PO Box 9649, 31096 Haifa, Israel

* Corresponding author. Tel: +972 4 829 5303; fax: +972 4 852 4758. E-mail address: mdlior{at}tx.technion.ac.il

The adult human heart has limited regenerative capacity and therefore any significant myocardial damage results in progressive deterioration in its function. Cell-based cardiac repair represents an exciting approach for rebuilding the injured heart. Consequentially, during the last decade, significant efforts have been made to assess the potential role of skeletal myoblasts, foetal cardiomyocytes, bone marrow stem cells, endothelial progenitors, resident cardiac progenitor cells, and embryonic stem cells (ESC) to restore the myocardial performance. Clinical translation of these basic studies has progressed rapidly with several Phase I and II clinical trials, utilizing autologous bone marrow cells and skeletal myoblasts, being well underway. In this review, we will describe these basic and clinical efforts. A specific emphasis will be placed on the potential role of human ESC for myocardial repair. These unique pluripotent cell lines can be propagated in the undifferentiated state in culture and coaxed to differentiate into cell derivatives of all three germ layers, including cardiomyocytes. The potential applications of this unique differentiating system in the emerging field of cardiovascular regenerative medicine will be discussed with special emphasis on the steps required to fully harness their unique potential.

Key Words: Stem cells • Cell therapy • Heart failure • Ischaemic heart disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.